Codexis to Participate in Informex USA 2013 Conference
-Company to Highlight its Enzymatic Technology Breakthroughs and Market
Opportunities in Fine Chemicals Sector-
REDWOOD CITY, Calif. -- February 15, 2013
Codexis, Inc. (NASDAQ: CDXS), a developer of world-leading enzymes and
processes for the production of pharmaceuticals, biofuels and bio-based
chemicals, announced today that it will exhibit the Company’s enzymatic
approaches for the fine chemicals industry at the Informex USA 2013
Conference, being held at the Anaheim Convention Center in Anaheim, Calif.,
from February 19-22, 2013.
The Company will use the opportunity to discuss its technology breakthroughs
that enable enzymatic processes to achieve greater cost savings and speed to
market for a variety of fine and specialty chemicals.
“Codexis continues to show that its unique and differentiated enzymatic
approach allows for exciting opportunities across the pharmaceutical and
chemical fields,” said John Nicols, President and CEO of Codexis. “Our
advanced enzymatic processes allow for more efficient production than
traditional chemistry approaches. We look forward to further demonstrating the
large impact of our technology platform and are highly focused on accelerating
the adoption of our enzymatic approach through partnerships among leading
players in the fine chemicals industry.”
Codexis’ exhibit at the conference will be located in Booth 2423H of the Green
Exchange Gallery at the Anaheim Convention Center from February 19-22, 2013.
About Codexis, Inc.
Codexis, Inc. is a developer of world-leading enzymes and processes for the
production of pharmaceuticals, biofuels and bio-based chemicals. Codexis'
product lines include CodeXyme® cellulase enzymes and CodeXol™ detergent
alcohol. Partners and customers include global leaders such as Merck, Pfizer
and Arch Pharmalabs. For more information, see www.codexis.com.
Forward Looking Statements
This press release contains forward-looking statements relating to potential
commercial opportunities for Codexis’ technologies in the pharmaceutical and
fine chemicals fields. You should not place undue reliance on these
forward-looking statements because they involve known and unknown risks,
uncertainties and other factors that are, in some cases, beyond our control
and could materially affect actual results. Factors that could materially
affect actual results include our dependence on a limited number of products
in our pharmaceutical business; potential adverse affects to our business if
our customers’ pharmaceutical products are not received well in the markets;
and our ability to develop and commercialize new products for the
pharmaceutical market. Additional factors that could materially affect actual
results can be found in Codexis’ Quarterly Report on Form 10-Q for the period
ended September 30, 2012 filed with the Securities and Exchange Commission on
November 7, 2012, including under the caption “Risk Factors.” Codexis
expressly disclaims any intent or obligations to update these forward-looking
statements, except as required by law.
Stern Investor Relations
Paul Cox, 212-362-1200
Press spacebar to pause and continue. Press esc to stop.